Diabetes research and clinical practice · 2026
Impact of glucagon-like peptide-1 receptor agonists with guideline-directed medical therapy in patients with heart failure with reduced ejection fraction and type 2 diabetes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kokura Yuki, Kishimori Takefumi, Kato Takao, Iwasaki Yoshihiro, Wada Atsuyuki, Tani Akira, Yamaji Ryosuke, Koike Jumpei, Matsumoto Takehiro, Yagi Takafumi, Sekine Osamu, Okada Masaharu
Аннотация
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are treatment options for Type 2 diabetes (T2D), but their efficacy in patients with heart failure with reduced ejection fraction (HFrEF) remains unclear. We evaluated the association of GLP-1 RAs added to guideline-directed medical therapy (GDMT) with all-cause death and hospitalization in patients with HFrEF and T2D.
METHODS: We conducted a retrospective cohort study using the TriNetX platform. Patients with HFrEF and T2D were identified between 2018 and 2023 (N = 579,171). Of these, 3,379 received all of GDMTs with GLP-1 RAs, and 14,712 received all of GDMTs without GLP-1 RAs. After propensity score matching, 3,158 patients were included in each group. Primary outcome was all-cause death over 18 months; secondary outcome was hospitalization.
RESULTS: All of GDMTs with GLP-1 RAs were associated with a lower risk of all-cause death than all of GDMTs without GLP-1 RAs (10.5 % vs. 14.4 %; hazard ratio [HR], 0.71; 95 % confidence interval [CI], 0.62-0.83). Hospitalization did not differ significantly between groups (63.7 % vs. 60.1 %; HR, 1.05; 95 % CI, 0.98-1.12).
CONCLUSION: In patients with HFrEF and T2D, all of GDMTs with GLP-1 RAs were associated with a lower risk of all-cause death than all of GDMTs without GLP-1 RAs.
METHODS: We conducted a retrospective cohort study using the TriNetX platform. Patients with HFrEF and T2D were identified between 2018 and 2023 (N = 579,171). Of these, 3,379 received all of GDMTs with GLP-1 RAs, and 14,712 received all of GDMTs without GLP-1 RAs. After propensity score matching, 3,158 patients were included in each group. Primary outcome was all-cause death over 18 months; secondary outcome was hospitalization.
RESULTS: All of GDMTs with GLP-1 RAs were associated with a lower risk of all-cause death than all of GDMTs without GLP-1 RAs (10.5 % vs. 14.4 %; hazard ratio [HR], 0.71; 95 % confidence interval [CI], 0.62-0.83). Hospitalization did not differ significantly between groups (63.7 % vs. 60.1 %; HR, 1.05; 95 % CI, 0.98-1.12).
CONCLUSION: In patients with HFrEF and T2D, all of GDMTs with GLP-1 RAs were associated with a lower risk of all-cause death than all of GDMTs without GLP-1 RAs.